Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Faculty Opinions recommendation of Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 9, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717958540.793464389 Get It

Faculty Opinions recommendation of Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Katzka, David A.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 9, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717958732.793464387 Get It

I am 80 going on 18: exercise and the fountain of youth
Barnes, Jill N. , Joyner, Michael J. , Barnes, J N

Journal of Applied Physiology | November 9, 2012 | Volume: 114 | Issue: 1 | Pages: 1-2

10.1152/japplphysiol.01313.2012 | PMID 23139369 Get It

PATIENT SELF-ASSESSMENT FACTORS PREDICTIVE OF PERSISTENT DEPRESSIVE SYMPTOMS 6 MONTHS AFTER ENROLLMENT IN COLLABORATIVE CARE MANAGEMENT
Angstman, Kurt B. , Shippee, Nathan D. , MacLaughlin, Kathy L. , Rasmussen, Norman H., Wilkinson, John M. , Williams, Mark D. , Katzelnick, David J., Shippee, Nathan

Depression and Anxiety | November 8, 2012 | Volume: 30 | Issue: 2 | Pages: 143-148

10.1002/da.22020 | PMID 23139162 Get It

Human MCS5A1 candidate breast cancer susceptibility gene FBXO10 is induced by cellular stress and correlated with lens epithelium-derived growth factor (LEDGF)
Xu, Xin , Powell, David W. , Lambring, Courtney J., Puckett, Aaron H., Deschenes, Lucas , Prough, Russell A. , Poeschla, Eric M. , Samuelson, David J.

Molecular Carcinogenesis | November 8, 2012 | Volume: 53 | Issue: 4 | Pages: 300-313

10.1002/mc.21977 | PMID 23138933 Get It

Commentary on “Single-Port Laparoscopic Colorectal Surgery: Early Clinical Experience”
Metzger, Philip P.

Journal of Laparoendoscopic & Advanced Surgical Techniques | November 8, 2012 | Volume: 22 | Issue: 9 | Pages: 858-858

10.1089/lap.2012.9989 | PMID 23137110 Get It

An allergic phenotype and the use of steroid inhalers predict eosinophilic oesophagitis in patients with asthma
Harer, Kimberly, Enders, Felicity , Lim, Kaiser G. , Alexander, Jeffrey A. , Katzka, David A. , Enders, Felicity T , Lim, Kaiser G

Alimentary Pharmacology & Therapeutics | November 8, 2012 | Volume: 37 | Issue: 1 | Pages: 107-113

10.1111/apt.12131 | PMID 23134444 Get It

SummaryBackgroundPatients with eosinophilic oesophagitis (EoE) commonly have asthma and atopy.AimsTo determine the predictive factors of EoE in patients with asthma.MethodsA retrospective analysis of a large database identified 156 asthma patients with EoE and 276 patients without EoE between 2000 and 2010. Clinical and laboratory characteristics were first analyzed in half of each group. Significant differences and modelling were then applied to the other half of each group in a split half analysis.ResultsOdds ratios and P‐values found to predict the presence of EoE in asthma patients were: allergic vs. non‐allergic asthma (4.07, <0.01), food allergies (45, <0.01), allergic rhinitis (2.13, =0.01) and peripheral eosinophilia (4.51, <0.01). The use of inhaled corticosteroids was negatively associated with EoE (0.41, <0.01) for asthma patients and (0.37, P < 0.01) for allergic type asthma patients. EoE patients were also younger (27.4 vs. 41.6 years old, P < 0.01). By logistic regression analysis, allergic asthma, presence of peripheral eosinophilia and use of inhaled steroids remained significant. From these parameters, a 3.5‐point scoring system model for EoE in asthma was formed with an ROC = 0.787 on split analysis.ConclusionsIn descending order, peripheral eosinophilia, allergic asthma and allergic rhinitis are associated with EoE in patients with asthma. Steroid inhalers appear to have a protective effect against EoE. An accurate and simple scoring system can be used as a screening tool to predict the presence of EoE in patients with asthma and dysphagia. EoE should be viewed as part of a generalised allergic phenotype rather than isolated oesophageal disease.
Fat mass and obesity gene and cognitive decline
Bressler, Jan , Fornage, Myriam , Demerath, Ellen W. , Monda, Keri L., Penman, Alan D. , Boerwinkle, Eric , Knopman, David S. , North, Kari E. , Mosley, Thomas H.

Neurology | November 8, 2012 | Volume: 80 | Issue: 1 | Pages: 92-99

10.1212/wnl.0b013e3182768910 | PMID 23136261 Get It

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
Jameson, Gayle , Hamm, John , Alemany, Carlos, Anthony, Stephen P. , Basche, M., Ramanathan, Ramesh K., Tibes, Raoul , Cohn, Allen Lee, Hinshaw, Ioana, Jotte, Robert M. , Rosen, Lee S. , Hoch, Ute , Eldon, Michael A., Medve, Robert A., Schroeder, Katrina, White, Erica, Hoff, Daniel D. Von , Weiss, Glen J. , Borad, Mitesh J.

Clinical Cancer Research | November 8, 2012 | Volume: 19 | Issue: 1 | Pages: 268-278

10.1158/1078-0432.ccr-12-1201 | PMID 23136196 Get It

Abstract Purpose: This study was designed to establish the maximum tolerated dose (MTD) and to evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol. Experimental Design: Patients with refractory solid malignancies were enrolled and assigned to escalating-dose cohorts. Patients received 1 infusion of etirinotecan pegol weekly 3 times every 4 weeks (w × 3q4w), or every 14 days (q14d), or every 21 days (q21d), with MTD as the primary end point using a standard 3 + 3 design. Results: Seventy-six patients were entered onto 3 dosing schedules (58–245 mg/m2). The MTD was 115 mg/m2 for the w × 3q4w schedule and 145 mg/m2 for both the q14d and q21d schedules. Most adverse events related to study drug were gastrointestinal disorders and were more frequent at higher doses of etirinotecan pegol. Late onset diarrhea was observed in some patients, the frequency of which generally correlated with dose density. Cholinergic diarrhea commonly seen with irinotecan treatment did not occur in patients treated with etirinotecan pegol. Etirinotecan pegol administration resulted in sustained and controlled systemic exposure to SN-38, which had a mean half-life of approximately 50 days. Overall, the pharmacokinetics of etirinotecan pegol are predictable and do not require complex dosing adjustments. Confirmed partial responses were observed in 8 patients with breast, colon, lung (small and squamous cell), bladder, cervical, and neuroendocrine cancer. Conclusion: Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecan historical profile. The MTD recommended for phase II clinical trials is 145 mg/m2 q14d or q21d. Clin Cancer Res; 19(1); 268–78. ©2012 AACR.
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
Harinck, Femme , Hruban, Ralph H. , Offerhaus, G. Johan A. , Poley, Jan‐Werner , Kamel, Ihab R. , Nio, Yung, Schulick, Richard, Bassi, Claudio, Kluijt, Irma, Levy, Michael J. , Chak, Amitabh , Bruno, Marco J. , Vasen, Hans F. A. , Salvia, Roberto , Hammel, Pascal , Canto, Marcia Irene , Fockens, Paul , Goggins, Michael

Gut | November 8, 2012 | Volume: 62 | Issue: 3 | Pages: 339-347

10.1136/gutjnl-2012-303108 | PMID 23135763 Get It

Background Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. Objective To develop consortium statements on screening, surveillance and management of high-risk individuals with an inherited predisposition to PC. Methods A 49-expert multidisciplinary international consortium met to discuss pancreatic screening and vote on statements. Consensus was considered reached if ≥75% agreed or disagreed. Results There was excellent agreement that, to be successful, a screening programme should detect and treat T1N0M0 margin-negative PC and high-grade dysplastic precursor lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm). It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16 , BRCA 2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR. Consensus was not reached for the age to initiate screening or stop surveillance. It was agreed that initial screening should include endoscopic ultrasonography (EUS) and/or MRI/magnetic resonance cholangiopancreatography not CT or endoscopic retrograde cholangiopancreatography. There was no consensus on the need for EUS fine-needle aspiration to evaluate cysts. There was disagreement on optimal screening modalities and intervals for follow-up imaging. When surgery is recommended it should be performed at a high-volume centre. There was great disagreement as to which screening abnormalities were of sufficient concern to for surgery to be recommended. Conclusions Screening is recommended for high-risk individuals, but more evidence is needed, particularly for how to manage patients with detected lesions. Screening and subsequent management should take place at high-volume centres with multidisciplinary teams, preferably within research protocols.